Readers! This is Sy.
The Food and Drug Administration is taking what, for an agency that's generally known for its caution and under-the-radar regulatory approach, may be seen as an aggressive new tact against drug makers: Publicly calling out companies accused of delaying the entry of cheaper generic drugs to the market by preventing generic manufacturers from getting samples of expensive brand name medicines.
“Today, we're making public a list of companies that have potentially been blocking access to the samples of their branded products,” said FDA Commissioner Scott Gottlieb in a...Read more ...